Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In a large scale trial, Takeda's glucose lowering drug Actos has been shown to significantly reduce the occurrence of fatal and non-fatal heart attacks in high-risk patients with type 2 diabetes who had a previous heart attack.
Subscribe to our email newsletter
The findings build on previous study results showing that Actos, an oral anti-diabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16% in the patient group.
The trial assessed the effects of Actos on cardiovascular morbidity and mortality in 2,445 high-risk patients who had previously had a heart attack, a population that tends to have a very poor prognosis.
The results show that in patients taking Actos on top of standard of care treatment the recurrence of fatal or non-fatal heart attacks was reduced by 28%, the risk of acute coronary syndrome or ACS (a term used to describe potentially life-threatening, acute cardiovascular events) was reduced by 37%, and there was a 19% risk reduction in the cardiac composite endpoint of non-fatal heart attacks, coronary revascularization, ACS and cardiac death
“These results are very meaningful for the diabetes community, especially when you consider that people with type 2 diabetes are more likely than those without diabetes to die from a heart attack and to have a second event,” said Dr Robert Spanheimer, medical director for diabetes and metabolism at Takeda Pharmaceuticals North America.